Cargando…

PANORAMIC: important insights into molnupiravir use in COVID-19

Detalles Bibliográficos
Autores principales:	Kidd, Michael R, Kelly, Paul M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779907/ https://www.ncbi.nlm.nih.gov/pubmed/36566762 http://dx.doi.org/10.1016/S0140-6736(22)02593-4

Ejemplares similares

Molnupiravir for COVID-19
Publicado: (2022)

The importance of trustworthiness: lessons from the COVID-19 pandemic
por: Leonard, Mary B., et al.
Publicado: (2021)

The important role of serology for COVID-19 control
por: Winter, Amy K, et al.
Publicado: (2020)

Importance of modelling for cancer management during COVID-19
por: Paris, Enrique
Publicado: (2021)

Importance of understanding the reinfection risk of COVID-19 in children
por: Crawford, Nigel W
Publicado: (2022)

Controlled obesity status: a rarely used concept, but with particular importance in the COVID-19 pandemic and beyond
por: Halpern, B., et al.
Publicado: (2020)

Managing COVID-19 importation risks in a heterogeneous world
por: Cauchemez, Simon, et al.
Publicado: (2021)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)

Insights from nanomedicine into chloroquine efficacy against COVID-19
por: Hu, Tony Y., et al.
Publicado: (2020)

Vascularite rétinienne post-Covid-19 et Molnupiravir
por: Lassouli, I., et al.
Publicado: (2022)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021)

The COVID-19 pandemic and epidemiologic insights from recession-related suicide mortality
por: Bastiampillai, Tarun, et al.
Publicado: (2020)

New insights into the association between body-mass index and severe COVID-19
por: Bhaskaran, Krishnan
Publicado: (2021)

The Zen of XEN: insight into differentiation, metabolism and genomic integrity
por: Gatie, Mohamed I., et al.
Publicado: (2018)

Molnupiravir in COVID-19: A systematic review of literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

What will be the role of molnupiravir in the treatment of COVID-19 infection?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Molnupiravir and Its Antiviral Activity Against COVID-19
por: Tian, Lili, et al.
Publicado: (2022)

Molnupiravir: A new candidate for COVID‐19 treatment
por: Pourkarim, Fariba, et al.
Publicado: (2021)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
por: Yip, Ashley Jia Wen, et al.
Publicado: (2022)

The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions
por: Chua, Felix, et al.
Publicado: (2020)

RdRp inhibitors and COVID-19: Is molnupiravir a good option?
por: Hashemian, Seyed Mohammad Reza, et al.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
por: Chang, Yi-Chin, et al.
Publicado: (2023)

The effect of molnupiravir on post-acute outcome of COVID-19 survivors
por: Hsu, Wan-Hsuan, et al.
Publicado: (2023)

Nirmatrelvir and Molnupiravir and Post–COVID-19 Condition in Older Patients
por: Fung, Kin Wah, et al.
Publicado: (2023)

The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19
por: Cheng, Shih-Lung, et al.
Publicado: (2023)

NZ's Pharmac negotiates deal for molnupiravir to treat COVID-19
Publicado: (2021)

Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India
por: Sinha, Shubhadeep, et al.
Publicado: (2022)

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
por: Butler, Christopher C, et al.
Publicado: (2023)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023)

The impact of COVID-19 pandemic on hospital admissions for nine diseases in Iran: insight from an interrupted time series analysis
por: Ahmadi, Sina, et al.
Publicado: (2022)

The impact of the COVID-19 pandemic on cancer care
por: Richards, Mike, et al.
Publicado: (2020)

Clinical course and mortality risk of severe COVID-19
por: Weiss, Paul, et al.
Publicado: (2020)

Antimicrobial use, drug-resistant infections and COVID-19
por: Rawson, Timothy M., et al.
Publicado: (2020)

Increased risk of severe COVID-19 outcomes in patients with rheumatoid arthritis and interstitial lung disease
por: Kelly, Clive
Publicado: (2022)

Haemoperfusion should only be used for COVID-19 in the context of randomized trials
por: Clark, Edward G., et al.
Publicado: (2020)

The impact of patient and public involvement on COVID-19 immunology research: experiences from the UK Coronavirus Immunology Consortium
por: Aquino, Erika Neves, et al.
Publicado: (2023)

A nomogram for use of non-invasive respiratory strategies in COVID-19
por: Hess, Dean R
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_toajsldahq61dc1ceo4d6gg2ld